找回密码
 立即注册

微信扫码登录

搜索

[晚期无驱动一线] EVOKE-03/KEYNOTE D46:Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC

[复制链接]
阳光肺科 发表于 2026-9-12 04:45:54 | 显示全部楼层 |阅读模式
Primary Results from Phase 3 EVOKE-03/KEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC
G. Mountzios1, M. Tiseo2, N. Katakami3, T. Ciuleanu4, S. Lu5, D. Kowalski6, J.C-H. Yang7, M.A.N. Sendur8, S. Ahmed9, S. Baka10, M. Janning11, X. Yu12, Y. Li12, Y. Sidi13, J. Yuan13, M. Moskovitz14
1Henry Dunant Hospital Center, Athens/GR ,2Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica, Parma/IT ,3Takarazuka City Hospital, Takarazuka, Hyogo,/JP ,4Institutul Oncologic-Oncologie

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2026-11-23 00:26

Powered by Discuz! X3.5

© 2001-2026 Discuz! Team.

快速回复 返回顶部 返回列表